Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2018
Reporting Period: Specific event date of December 19, 2018 (conversion notice received) and December 20, 2018 (shares issued).
Key Financial Metrics
This filing reports a specific capital transaction rather than periodic financial performance. Consequently, revenue, profit, cash flow, and margin data are not provided in this document.
- Debt Reduction: $325,000 principal amount of convertible note retired.
- Equity Issuance: 162,500 shares of common stock issued.
- Liquidity Impact: No cash consideration was paid; the transaction was a debt-for-equity swap.
Material Changes
The primary material change is the conversion of outstanding debt into equity.
- Debt Elimination: The Company retired all outstanding debt instruments associated with the specific convertible note issued on June 6, 2018.
- Capital Structure: The Company's share count increased by 162,500 shares, while its debt load decreased by $325,000.
Guidance, Outlook, and Risks
Management Commentary: The filing states the issuance was made in reliance on the exemption from registration under Section 3(a)(9) of the Securities Act of 1933. This exemption applied because the issuance was made to an existing security holder, no additional consideration was paid, and no commission or remuneration was involved.
Outlook and Risks: The filing text does not provide forward-looking guidance, general risk factors, or discussion of contingencies beyond the specific mechanics of this transaction.
Investor Verification Checklist
- Verify the total number of outstanding shares post-conversion to assess dilution impact.
- Confirm the terms of the original convertible note (interest rate, maturity date) to understand the cost of capital avoided.
- Check subsequent filings to determine if other convertible notes remain outstanding or if this was the sole debt instrument.
- Review the Company's cash position in the most recent 10-K or 10-Q to understand liquidity needs following the debt retirement.